Ipsen Aktie [WKN: A0ESMG / ISIN: FR0010259150]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ipsen

29.11.17		Ipsen announces publication in Neurology of results of two studies demonstrating the efficacy and safety of Dysport® (abobotulinumtoxinA) in adult patients with lower limb spasticity (Businesswire)
14.11.17		IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
26.10.17		Ipsen Delivers Strong Sales Growth of 22.6%1 for the Third Quarter of 2017 and Confirms Full Year Guidance (Businesswire)
16.10.17		Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma (Businesswire)
11.10.17		IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
19.09.17		Ipsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy (Businesswire)
18.09.17		U.S. FDA Approves New Indication for Ipsen's Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome (Businesswire)
12.09.17		IPSEN: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
10.09.17		Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 (Businesswire)
08.09.17		Ipsen receives validation from European Medicines Agency for the application of a new indication for Cabometyx® (cabozantinib) for first-line treatment of advanced renal cell carcinoma in adults (Businesswire)
04.09.17		Ipsen Announces 16 Abstract Presentations of Oncology Portfolio at European Society of Medical Oncology Congress (Businesswire)
15.08.17		IPSEN: Disclosure of Transactions in Own Shares between 07/08/2017 and 11/08/2017 (Businesswire)
11.08.17		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
08.08.17		IPSEN: Disclosure of transactions in own shares between 31/07/2017 and 04/08/2017 (Businesswire)
01.08.17		IPSEN: Disclosure of Transactions in Own Shares Between 24/07/2017 and 28/07/2017 (Businesswire)
25.07.17		IPSEN: Disclosure of transactions in own shares between 17/07/2017 and 21/07/2017 (Businesswire)
18.07.17		IPSEN: Disclosure of transactions in own shares between 10/07/2017 and 14/07/2017 (Businesswire)
18.07.17		Half-year IPSEN liquidity contract statement entered into with NATIXIS (Businesswire)
03.07.17		Ipsen: Somatuline® Autogel® 120 mg Receives Japanese Approval for a New Indication for the Treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumors (Businesswire)
16.06.17		Ipsen Announces FDA Approval of Dysport® (Abobotulinumtoxina) for the Treatment of Lower Limb Spasticity in Adults (Businesswire)
08.06.17		Ipsen initiates share buy-back program to cover its free performance share allocation plan (Businesswire)
01.06.17		IPSEN: Description of the regulatory framework of the share repurchase program proposed by the Board of Directors to the approval of the Combined Shareholders’ Meeting to be held on 7 June 2017 (Businesswire)
14.04.17		Ipsen Appoints Dr. Alexandre Lebeaut as Executive Vice-President, R&D, and Chief Scientific Officer (Businesswire)
10.03.17		Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
02.03.17		Ipsen Appoints Benoit Hennion as Executive Vice President and President, Primary Care (Businesswire)
10.01.17		IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
21.12.16		Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include Canada (Businesswire)
13.12.16		Ipsen Announces Its Corporate Agenda for 2017 (Businesswire)
09.12.16		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
22.11.16		IPSEN: Disclosure of transactions in own shares between 14/11/2016 and 18/11/2016 (Businesswire)
15.11.16		IPSEN: Disclosure of Transactions in Own Shares between 07/11/2016 and 11/11/2016 (Businesswire)
10.11.16		Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
08.11.16		IPSEN: Disclosure of Transactions in Own Shares between 31/10/2016 and 04/11/2016 (Businesswire)
01.11.16		IPSEN: Disclosure of Transactions in Own Shares between 10/24/2016 and 10/28/2016 (Businesswire)
26.10.16		Ipsen Reports 12.2%1 Sales Growth for the Third Quarter of 2016 and Raises Full Year Guidance (Businesswire)
25.10.16		IPSEN: Disclosure of transactions in own shares between 17/10/2016 and 21/10/2016 (Businesswire)
10.10.16		Ipsen: Monthly information regarding the total number of voting rights and total number of shares of the Company (Businesswire)
27.09.16		Ipsen Announces Data Presentations of Cabozantinib (Cabometyx™), Lanreotide (Somatuline® Autogel®) and Telotristat Ethyl* at the European Society for Medical Oncology (ESMO) 2016 Congress (Businesswire)
09.09.16		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
08.08.16		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
01.08.16		Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older (Businesswire)
22.07.16		Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx™ (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy (Businesswire)
11.07.16		David Meek appointed as Chief Executive Officer of Ipsen (Businesswire)
08.07.16		Half-Year IPSEN Liquidity Contract Statement Entered into with NATIXIS (Businesswire)
08.07.16		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
27.06.16		Ipsen initiates a new share buy-back program to cover its free performance share allocation plan (Businesswire)
09.06.16		Ipsen Successfully Issues Inaugural €300 Million 7-Year Notes (Businesswire)
07.06.16		Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company (Businesswire)
06.06.16		The Ipsen Group Launches an Employee Shareholding Plan (Businesswire)
31.05.16		Combined Shareholders’ Meeting of IPSEN S.A. held on 31 May 2016 (Businesswire)

Erste Seite Zurück | ... | 3 | 4 | 5 | 6 | Weiter

Newssuche

Meistgelesene Nachrichten

Diese AI-Aktie ist Cathie Woods neuer Favorit

JPMorgan: Bitcoin-Miner setzen auf Unternehmensmodell von MicroStrategy

NEL sichert sich Steuergutschrift in Millionenhöhe - Aktie sackt ab

ATX-Papier voestalpine-Aktie: So viel Verlust hätte ein voestalpine-Investment von vor einem Jahr eingefahren

Aktien von PVA TePla und SMA Solar springen hoch, VERBIO-Aktie stürzt ab: Jefferies-Analyst passt zahlreiche Bewertungen an

D-Wave Quantum-Aktie, IonQ-Aktie und Rigetti-Aktie fallen: Aktienrutsch geht trotz Beruhigungssignalen weiter

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	15.01.2025 13:04
Kaufwert:	EUR
	Hinzufügen Speichern